Myron Strickland, MD
Obstetrics & Gynecology · Fayetteville, NCNPI 1336189505
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,175 of the $4,023 with a category attached, or 78.9%. It is spread thinly across 40 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,184 and has fallen 78.2% since, to $258 in 2025.
Across 190 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$818
- Daiichi Sankyo Inc.$399
- Pfizer$332
- AbbVie$240
- Exeltis, USA Inc.$181
- Johnson & Johnson$175
- plus $2K from 34 others
Across 3 payments — averaging $868.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$3K
What the payments were for
- Travel & lodging$73018%
- Food & beverage$3,17579%
- Education$1183%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 2 | $818 |
| Daiichi Sankyo Inc. | 23 | $399 |
| Pfizer | 26 | $332 |
| AbbVie | 15 | $240 |
| Exeltis, USA Inc. | 10 | $181 |
| Johnson & Johnson | 4 | $175 |
| Astellas Pharma US Inc | 5 | $150 |
| Organon | 9 | $144 |
| Coopersurgical, Inc. | 9 | $132 |
| Exact Sciences | 7 | $131 |
| Novo Nordisk | 9 | $131 |
| Therapeuticsmd, Inc. | 7 | $124 |
| Mayne Pharma Commercial LLC | 8 | $114 |
| Agile Therapeutics, Inc. | 6 | $98 |
| Evofem Biosciences, Inc. | 5 | $91 |
| Bayer | 5 | $80 |
| Hologic Sales And Service, LLC | 4 | $76 |
| Mission Pharmacal Company | 5 | $67 |
| Biogen | 3 | $61 |
| Avion Pharmaceuticals | 3 | $48 |
| Shield Therapeutics Inc | 2 | $44 |
| Aspira Women's Health Inc | 2 | $42 |
| Urovant Sciences Inc | 2 | $34 |
| AMAG Pharmaceuticals, Inc. | 2 | $29 |
| Aroa Biosurgery Incorporated | 1 | $26 |
| Lupin Inc. | 2 | $26 |
| Dexcom, Inc. | 1 | $23 |
| Roche Diagnostics Corporation | 1 | $20 |
| LSI Solutions Inc | 1 | $20 |
| Myovant Sciences Inc. | 1 | $19 |
| Avanos Medical | 1 | $18 |
| Mylan Pharmaceuticals Inc. | 1 | $17 |
| Pharmacosmos Therapeutics Inc. | 1 | $17 |
| Medtronic | 1 | $15 |
| Neos Therapeutics, LP | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Eagle Pharmaceuticals, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Millicent US Inc | 1 | $13 |
| Minerva Surgical, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,023 in reported general payments places this provider in the 85th percentile of 1,344 obstetrics & gynecology providers in North Carolina.
See all obstetrics & gynecology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 40 | $14,802 |
| MyrbetriqMirabegron | 21 | $12,292 |
| Estradiol | 260 | $12,039 |
| PremproEstrogen,con/M-Progest Acet | 22 | $11,538 |
| ValacyclovirValacyclovir Hcl | 33 | $2,299 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 79 | $1,845 |
| Tolterodine Tartrate ErTolterodine Tartrate | 39 | $1,838 |
| FenofibrateFenofibrate Nanocrystallized | 13 | $486 |
| Ibandronate Sodium | 24 | $474 |
| Solifenacin Succinate | 15 | $436 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 14 | $368 |
| Simvastatin | 30 | $346 |
| Ketorolac Tromethamine | 20 | $345 |
| Clobetasol Propionate | 17 | $332 |
| Celecoxib | 11 | $178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin, Prempro | $332 | $26,34062 claims |
| Astellas Pharma US IncMyrbetriq | $150 | $12,29221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,344 obstetrics & gynecology providers in North Carolina.
Other obstetrics & gynecology in Fayetteville
- Jerry MatkinsCharlotte$481K
- Laura McKainWilmington$475K
- Leslie Hansen-LindnerCharlotte$372K
- Robin MatthewsClyde$217K
- Haywood BrownDurham$165K
- Jack IngeRaleigh$157K
- Geeta SwamyDurham$142K
- Karie LafleurAsheville$135K
- Ty RobinsonHigh Point$114K
- Shan BiscetteCharlotte$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.